Cargando…
A Brief Overview of Adaptive Designs for Phase I Cancer Trials
SIMPLE SUMMARY: Phase I cancer trials are important for new drug developments to test the safety and optimal dosage of cancer drugs which are usually toxic. Understanding biostatistical methodologies of these designs is important for developing phase I studies that are both safe for the participants...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946506/ https://www.ncbi.nlm.nih.gov/pubmed/35326715 http://dx.doi.org/10.3390/cancers14061566 |
_version_ | 1784674209688977408 |
---|---|
author | Saxena, Anshul Rubens, Muni Ramamoorthy, Venkataraghavan Zhang, Zhenwei Ahmed, Md Ashfaq McGranaghan, Peter Das, Sankalp Veledar, Emir |
author_facet | Saxena, Anshul Rubens, Muni Ramamoorthy, Venkataraghavan Zhang, Zhenwei Ahmed, Md Ashfaq McGranaghan, Peter Das, Sankalp Veledar, Emir |
author_sort | Saxena, Anshul |
collection | PubMed |
description | SIMPLE SUMMARY: Phase I cancer trials are important for new drug developments to test the safety and optimal dosage of cancer drugs which are usually toxic. Understanding biostatistical methodologies of these designs is important for developing phase I studies that are both safe for the participants and which use optimal dosages for better outcomes. Currently there are several phase I designs that are being refined and modified for better outcomes and newer designs are being continuously developed. In this review article, we described several important phase I study designs to provide a brief overview of existing methods. Our review could be helpful to the research community who intent to have a better and yet a concise summary of existing methods. ABSTRACT: Phase I studies are used to estimate the dose-toxicity profile of the drugs and to select appropriate doses for successive studies. However, literature on statistical methods used for phase I studies are extensive. The objective of this review is to provide a concise summary of existing and emerging techniques for selecting dosages that are appropriate for phase I cancer trials. Many advanced statistical studies have proposed novel and robust methods for adaptive designs that have shown significant advantages over conventional dose finding methods. An increasing number of phase I cancer trials use adaptive designs, particularly during the early phases of the study. In this review, we described nonparametric and algorithm-based designs such as traditional 3 + 3, accelerated titration, Bayesian algorithm-based design, up-and-down design, and isotonic design. In addition, we also described parametric model-based designs such as continual reassessment method, escalation with overdose control, and Bayesian decision theoretic and optimal design. Ongoing studies have been continuously focusing on improving and refining the existing models as well as developing newer methods. This study would help readers to assimilate core concepts and compare different phase I statistical methods under one banner. Nevertheless, other evolving methods require future reviews. |
format | Online Article Text |
id | pubmed-8946506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89465062022-03-25 A Brief Overview of Adaptive Designs for Phase I Cancer Trials Saxena, Anshul Rubens, Muni Ramamoorthy, Venkataraghavan Zhang, Zhenwei Ahmed, Md Ashfaq McGranaghan, Peter Das, Sankalp Veledar, Emir Cancers (Basel) Review SIMPLE SUMMARY: Phase I cancer trials are important for new drug developments to test the safety and optimal dosage of cancer drugs which are usually toxic. Understanding biostatistical methodologies of these designs is important for developing phase I studies that are both safe for the participants and which use optimal dosages for better outcomes. Currently there are several phase I designs that are being refined and modified for better outcomes and newer designs are being continuously developed. In this review article, we described several important phase I study designs to provide a brief overview of existing methods. Our review could be helpful to the research community who intent to have a better and yet a concise summary of existing methods. ABSTRACT: Phase I studies are used to estimate the dose-toxicity profile of the drugs and to select appropriate doses for successive studies. However, literature on statistical methods used for phase I studies are extensive. The objective of this review is to provide a concise summary of existing and emerging techniques for selecting dosages that are appropriate for phase I cancer trials. Many advanced statistical studies have proposed novel and robust methods for adaptive designs that have shown significant advantages over conventional dose finding methods. An increasing number of phase I cancer trials use adaptive designs, particularly during the early phases of the study. In this review, we described nonparametric and algorithm-based designs such as traditional 3 + 3, accelerated titration, Bayesian algorithm-based design, up-and-down design, and isotonic design. In addition, we also described parametric model-based designs such as continual reassessment method, escalation with overdose control, and Bayesian decision theoretic and optimal design. Ongoing studies have been continuously focusing on improving and refining the existing models as well as developing newer methods. This study would help readers to assimilate core concepts and compare different phase I statistical methods under one banner. Nevertheless, other evolving methods require future reviews. MDPI 2022-03-18 /pmc/articles/PMC8946506/ /pubmed/35326715 http://dx.doi.org/10.3390/cancers14061566 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Saxena, Anshul Rubens, Muni Ramamoorthy, Venkataraghavan Zhang, Zhenwei Ahmed, Md Ashfaq McGranaghan, Peter Das, Sankalp Veledar, Emir A Brief Overview of Adaptive Designs for Phase I Cancer Trials |
title | A Brief Overview of Adaptive Designs for Phase I Cancer Trials |
title_full | A Brief Overview of Adaptive Designs for Phase I Cancer Trials |
title_fullStr | A Brief Overview of Adaptive Designs for Phase I Cancer Trials |
title_full_unstemmed | A Brief Overview of Adaptive Designs for Phase I Cancer Trials |
title_short | A Brief Overview of Adaptive Designs for Phase I Cancer Trials |
title_sort | brief overview of adaptive designs for phase i cancer trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946506/ https://www.ncbi.nlm.nih.gov/pubmed/35326715 http://dx.doi.org/10.3390/cancers14061566 |
work_keys_str_mv | AT saxenaanshul abriefoverviewofadaptivedesignsforphaseicancertrials AT rubensmuni abriefoverviewofadaptivedesignsforphaseicancertrials AT ramamoorthyvenkataraghavan abriefoverviewofadaptivedesignsforphaseicancertrials AT zhangzhenwei abriefoverviewofadaptivedesignsforphaseicancertrials AT ahmedmdashfaq abriefoverviewofadaptivedesignsforphaseicancertrials AT mcgranaghanpeter abriefoverviewofadaptivedesignsforphaseicancertrials AT dassankalp abriefoverviewofadaptivedesignsforphaseicancertrials AT veledaremir abriefoverviewofadaptivedesignsforphaseicancertrials AT saxenaanshul briefoverviewofadaptivedesignsforphaseicancertrials AT rubensmuni briefoverviewofadaptivedesignsforphaseicancertrials AT ramamoorthyvenkataraghavan briefoverviewofadaptivedesignsforphaseicancertrials AT zhangzhenwei briefoverviewofadaptivedesignsforphaseicancertrials AT ahmedmdashfaq briefoverviewofadaptivedesignsforphaseicancertrials AT mcgranaghanpeter briefoverviewofadaptivedesignsforphaseicancertrials AT dassankalp briefoverviewofadaptivedesignsforphaseicancertrials AT veledaremir briefoverviewofadaptivedesignsforphaseicancertrials |